Objective: To investigate the relationship of anti-tuberculosis immunity with perforin (PFN), granzyme B (GzmB), interferon-gamma (IFN-gamma), and interleukin-2 (IL-2) expression by T lymphocyte subsets.
Methods: Sixty mice were randomly allocated into a tuberculosis group and a control group (n = 30 each). Surface markers of T lymphocytes were stained with CD(3)PerCP, CD(4)FTTC, CD(8)APC, and intracellular cytotoxic molecules with PE-PFN, PE-GzmB, PE-IFN-gamma, and PE-IL-2 multi-color-labeled monoclonal antibodies, and analyzed at the single cell level. The relation between T lymphocyte subsets expression PFN, GzmB, IFN-gamma, IL-2 and antituberculosis immunity by flow cytometer.
Results: (1) CD(4)(+), CD(8)(+), and CD(4)(+)CD(8)(+) (DP) T lymphocytes all expressed PFN, GzmB, IFN-gamma and IL-2 to some degrees. The expressions of PFN and GzmB were much higher in CD(8)(+) T lymphocytes than those in CD(4)(+) T lymphocytes, while the expressions of IFN-gamma and IL-2 were higher in CD(4)(+) T lymphocytes. (2) The counts of T lymphocyte subsets and the percentages of T lymphocyte subsets to total lymphocytes may or may not reflect the cellular immunity consistently. (3) There was no significant difference in T lymphocytes expressing PFN between the tuberculosis group and the control group. But the counts of CD(3)(+), CD(4)(+), DP and CD(8)(+) T lymphocytes and the percentages of CD(3)(+), DP and CD(8)(+) cells expressing GzmB were significantly increased in the tuberculosis group (t value from -3.72 to 4.13, all P < 0.05). (4) IFN-gamma expressing CD(3)(+) and CD(4)(+) lymphocytes were increased significantly in the tuberculosis group. The counts of CD(8)(+) and DP T lymphocytes and the percentages of CD(3)(+), CD(4)(+), CD(8)(+), and DP cells that expressed IL-2 were decreased significantly in the tuberculosis group (t value from 2.62 to 3.46, all P < 0.05).
Conclusion: CD(4)(+), CD(8)(+) and DP lymphocytes all can express PFN, GzmB, IFN-gamma and IL-2 at different degree levels.
Download full-text PDF |
Source |
---|
Front Immunol
January 2025
Laboratory of Molecular Immunology, Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia.
Introduction: Diffuse parenchymal lung diseases (DPLD) cover heterogeneous types of lung disorders. Among many pathological phenotypes, pulmonary fibrosis is the most devastating and represents a characteristic sign of idiopathic pulmonary fibrosis (IPF). Despite a poor prognosis brought by pulmonary fibrosis, there are no specific diagnostic biomarkers for the initial development of this fatal condition.
View Article and Find Full Text PDFFront Immunol
January 2025
Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
Background: Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, with tuberculosis infection (TBI), have a high probability of progressing to tuberculosis disease (TB). We aim to characterize the impact of IMID on the immune response to (Mtb) in patients with TBI and TB disease.
Methods: We enrolled TBI and TB patients with and without IMID.
BMC Health Serv Res
January 2025
Sydani Initiative for International Development, FCT, Abuja, Nigeria.
Background: Evidence from literature has established that tracing lost to follow-up clients is an effective strategy for complementing other mechanisms for infectious disease control like human immunodeficiency virus (HIV), tuberculosis, and other diseases such as Ebola. As a long-standing successful public health method of optimizing acceptance and/or adherence to infectious disease treatment tracing lost to follow-up clients is usually carried out by manually investigating individuals who absconded or are absent from treatments designed to manage and/or promote their health status. This study seeks to explore the role of mobile teams in tracing clients lost to follow-up for immunization.
View Article and Find Full Text PDFClin Pharmacokinet
January 2025
Facultés de Médecine et de Pharmacie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Background And Objective: Limited information is available on the pharmacokinetics of rifampicin (RIF) along with that of its active metabolite, 25-deacetylrifampicin (25-dRIF). This study aimed to analyse the pharmacokinetic data of RIF and 25-dRIF collected in adult patients treated for tuberculosis.
Methods: In adult patients receiving 10 mg/kg of RIF as part of a standard regimen for drug-susceptible pulmonary tuberculosis enrolled in the Opti-4TB study, plasma RIF and 25-dRIF concentrations were measured at various occasions.
NPJ Prim Care Respir Med
January 2025
Centre for Tuberculosis Research, Departments of Clinical Sciences and International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.
Evidence relating to peer support and community-based psychological and social (psychosocial) interventions to reduce stigma and depression among people with tuberculosis (TB) and their households is limited. This study aimed to engage with multisectoral stakeholders in Indonesia to co-develop a peer-led, community-based psychosocial intervention that is replicable, acceptable, and sustainable. We used a participatory action design and engaged key national, multisectoral stakeholders to ensure that the intervention co-design was relevant and appropriate to the TB health system and the sociocultural context of Indonesia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!